Guselkumab Archives - Medical Conferences

PsoBest registry: Biologics dominate treatment for moderate-to-severe psoriasis

Presented By

Prof. Matthias Augustin, University Medical Center Hamburg-Eppendorf, Germany

Trial

PsoBest registry

Conference

EADV 2024

Type

Peer-reviewed article

6 November 2024 12:23

The unfavourable role of obesity in psoriatic disease

Presented By

Prof. Ulrich Mrowietz, University Medical Center Schleswig-Holstein, Germany

Conference

IFPA 2024

Type

News article

17 July 2024 14:13

Biologics for psoriasis: towards oral therapies and less frequent dosing

Presented By

Prof. Bruce Strober, Yale University, CT, USA

Trial

LIMMItless; GUIDE; FRONTIER

Conference

IFPA 2023

Type

News article

17 July 2024 14:00

GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease

Presented By

Dr Remo Panaccione, University of Calgary, Canada

Trial

GALAXI

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 13:01

QUASAR maintenance study: Guselkumab effective and safe for UC

Presented By

Dr David Rubin, University of Chicago, USA

Trial

QUASAR

Conference

DDW 2024

Type

Peer-reviewed article

11 July 2024 12:58

GUIDE demonstrates: Hit hard and early in psoriasis

Presented By

Prof. Knut Schäkel, University Clinic Heidelberg, Germany

Trial

Phase 3, GUIDE

Conference

AAD 2024

Type

Peer-reviewed article

22 April 2024 16:36

QUASAR: Guselkumab improves QoL for patients with ulcerative colitis

Presented By

Prof. Julian Panés, Hospital Clinic de Barcelona, Spain

Trial

Phase 3, QUASAR

Conference

ECCO 2024

Type

Peer-reviewed article

18 April 2024 13:43

Guselkumab provides benefits in UC regardless of advanced therapy history

Presented By

Prof. Axel Dignass, Goethe University, Germany

Trial

Phase 3, QUASAR

Conference

UEGW 2023

Type

Peer-reviewed article

7 December 2023 15:42

Drug survival of guselkumab and risankizumab seems superior to other biologics

Presented By

Dr Zenas Yiu, University of Manchester, UK

Trial

BADBIR

Conference

EADV 2023

Type

Peer-reviewed article

28 November 2023 12:04

IL-23 inhibition reduces inflammatory biomarkers in pre-treated UC

Presented By

Prof. Julian Panés, Hospital Clínic Barcelona, Spain

Trial

Phase 2, QUASAR

Conference

UEGW 2022

Type

Peer-reviewed article

1 December 2022 21:53

Greater PASI reductions lead to less impairment in social and sexual life

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

SPIN 2022

Type

Peer-reviewed article

26 August 2022 10:32

Guselkumab shows encouraging safety and efficacy in ulcerative colitis

Presented By

Prof. Axel Dignass, Agaplesion Markus Hospital, Germany

Trial

Phase 2, QUASAR Induction

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:23

Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease

Presented By

Prof. Silvio Danese, Vita-Salute San Raffaele University, Italy

Trial

Phase 2, GALAXI-1

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:21

Guselkumab plus golimumab promising combination for ulcerative colitis

Presented By

Prof. Bruce Sands, Mount Sinai School of Medicine, NY, USA

Trial

Phase 2, VEGA

Conference

ECCO 2022

Type

Peer-reviewed article

12 April 2022 16:10

Selective IL-23 inhibition normalises gene expression in active PsA

Presented By

Ms Michelle Miron

Trial

Phase 3, DISCOVER-1&-2

Conference

PFGC 2021

Type

Peer-reviewed article

2 February 2022 13:48

PFGC 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

PFGC 2021

22 December 2021 08:12

Psoriatic arthritis: Guidelines and best practice

Trial

Phase 3, BE ACTIVE, PATERA

Conference

WPPAC 2021

Type

Peer-reviewed article

17 September 2021 11:19

Guselkumab efficacious in PsA patients with inadequate response to TNF inhibition

Presented By

Dr Laura Coates , University of Oxford, UK

Trial

Phase 3, COSMOS

Conference

EULAR 2021

Type

Peer-reviewed article

2 August 2021 22:06

Resolution of dactylitis or enthesitis is associated with improvements in joint and skin symptoms

Presented By

Prof. Dennis McGonagle, University of Leeds, UK

Trial

Phase 3, DISCOVER-1 & -2

Conference

ACR 2020

18 January 2021 10:51

ECLIPSE trial: skin clearance independent of PsA status at baseline

Presented By

Prof. Kristian Reich

Trial

Phase 3, ECLIPSE

Conference

AAD 2020

Type

Peer-reviewed article

7 August 2020 13:12

Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis

Presented By

Prof. Atul Deodhar, Oregon Health & Science University, USA

Trial

Phase 3, DISCOVER

Conference

ACR 2019

Type

Peer-reviewed article

4 February 2020 19:53

Advances in target-oriented therapy: psoriatic arthritis

Presented By

Prof. Wolf-Henning Boehncke, University of Geneva, Switzerland

Trial

ECLIPSA, TICOPA

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 23:48

Results from the ECLIPSE trial: does blocking IL-23 have better long-term outcomes in psoriasis?

Presented By

Prof. Kristian Reich, Georg-August-University Göttingen, Germany

Trial

ECLIPSE

Conference

SPIN 2019

Type

Peer-reviewed article

21 June 2019 18:23

Plaque psoriasis – Efficacy of guselkumab

Trial

Phase 3, VOYAGE 1, VOYAGE 2

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 20:06

Psoriasis and Biologics: The Beat Goes On

Presented By

Prof. Mark Lebwohl, Mount Sinai School of Medicine, USA

Conference

AAD 2019

Type

Peer-reviewed article

19 April 2019 14:06